Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278539 | 0.91 | PTPN11 (0.77) | PTPN11USP2ALDH1A1TSHR | |
| SCHEMBL2275960 | 0.87 | PTPN11 (1.00) | PTPN11 | |
| SCHEMBL12372382 | 0.86 | TP53 (0.85) | PTPN11USP2ALDH1A1TSHRTP53 | |
| SCHEMBL12372346 | 0.85 | PTPN11 (0.84) | PTPN11USP2ALDH1A1TSHR | |
| SCHEMBL12372326 | 0.84 | PTPN11 (0.83) | PTPN11ALDH1A1TP53 | |
| SCHEMBL12372317 | 0.84 | PTPN11 (0.85) | PTPN11USP2ALDH1A1TSHRTP53 | |
| SCHEMBL12372348 | 0.84 | PTPN11 (0.82) | PTPN11USP2ALDH1A1TSHR | |
| SCHEMBL17225360 | 0.83 | PTPN11 (0.84) | PTPN11ALDH1A1 | |
| SCHEMBL12372370 | 0.82 | PTPN11 (0.83) | PTPN11ALDH1A1TP53 | |
| SCHEMBL12372365 | 0.81 | PTPN11 (0.85) | PTPN11USP2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | PTPN11 16/4885USP2 1103/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.